enGene Holdings Inc. (NASDAQ:ENGN) Receives $34.40 Consensus Target Price from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $34.40.

A number of analysts have commented on ENGN shares. Guggenheim started coverage on shares of enGene in a report on Monday, April 15th. They set a “buy” rating and a $34.00 target price for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Morgan Stanley began coverage on shares of enGene in a report on Friday, March 8th. They set an “overweight” rating and a $40.00 target price for the company. UBS Group began coverage on shares of enGene in a research note on Thursday, March 28th. They issued a “buy” rating and a $37.00 price objective for the company. Finally, SVB Leerink began coverage on shares of enGene in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price objective for the company.

Insider Buying and Selling

In related news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the transaction, the insider now owns 3,036,153 shares in the company, valued at $45,542,295. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On enGene

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Altitude Crest Partners Inc. bought a new position in shares of enGene during the first quarter worth $2,039,000. Vivo Capital LLC bought a new position in enGene during the fourth quarter valued at $6,264,000. Janus Henderson Group PLC bought a new position in enGene during the first quarter valued at $17,095,000. Omega Fund Management LLC bought a new position in enGene during the fourth quarter valued at $10,441,000. Finally, BVF Inc. IL bought a new position in enGene during the fourth quarter valued at $20,777,000. Institutional investors own 64.16% of the company’s stock.

enGene Stock Down 0.6 %

Shares of ENGN stock opened at $13.14 on Friday. enGene has a 12 month low of $6.69 and a 12 month high of $43.00. The company has a 50 day simple moving average of $15.62 and a two-hundred day simple moving average of $11.90.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.